Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase
MWN-AI** Summary
Cardiac Biotech Solutions, Inc. (OTCID: CBSC) has taken a significant step in its strategic plan to penetrate the Chinese market with its MyCardia AT cardiac event monitoring device. As of January 15, 2026, the company has activated its production pipeline in China, partnering with Ebulent Medical (Shenzhen) Ltd., a certified medical device manufacturer recognized by the National Medical Products Administration (NMPA). This collaboration marks a pivotal advancement in CBSC’s growth strategy, which has seen recent successes in international markets, including regulatory approvals in Canada and distribution agreements in Central and South America.
CBSC has begun to deliver essential components and accessories for the MyCardia AT to Ebulent, which is now tasked with developing a manufacturing file and Device History File (DHF) to comply with NMPA regulations. The production facility is poised to initiate its first manufacturing run by the end of January 2026. A critical component of this process involves deploying the device in hospital settings across China for clinical testing, thereby leveraging the company's extensive experience, having surpassed five million patient procedures in prior clinical trials.
Once these clinical validations are successfully completed, Ebulent will file required documentation to register as CBSC's manufacturing partner with the NMPA. The partnership not only enhances CBSC's ability to gain regulatory approval but also positions the company for commercialization in China. Charles Martin, CEO of CBSC, emphasized that Ebulent's established regulatory framework significantly boosts their capacity for success.
With this initiative, CBSC continues to pursue its mission of delivering advanced cardiac monitoring solutions on a global scale, fostering a recurring revenue stream through innovative wearable technology connected via the AWS Cloud. As the situation develops, the company promises to keep stakeholders informed through press releases and regulatory updates.
MWN-AI** Analysis
Cardiac Biotech Solutions, Inc. (OTCID: CBSC) is making significant strides in its expansion into the Chinese market with the preparation for the NMPA submission phase for its MyCardia AT cardiac monitoring device. The collaboration with Ebulent Medical (Shenzhen) Ltd., a licensed NMPA manufacturer, positions CBSC favorably by leveraging Ebulent's established regulatory infrastructure to expedite the manufacturing and approval process.
The MyCardia AT, which integrates enhanced technology for cardiac monitoring, is poised to capture a share of the rapidly growing healthcare market in China. With a successful track record of over five million patient procedures, CBSC’s entry into China not only broadens its market presence but also underlines the demand for advanced cardiac monitoring solutions.
Investors should view the activation of the manufacturing pipeline and the progression to field testing as a robust indicator of CBSC's potential for strong revenue growth through its recurring revenue model. The device is designed for easy integration with cloud-based technology, enabling patient engagement through mobile applications, which aligns well with the increasing demand for accessible healthcare solutions.
However, it's important to consider the inherent risks associated with such ventures, including regulatory approvals and potential market competition. The company’s success depends heavily on its ability to navigate the intricacies of the NMPA approval process and to distinguish itself in a competitive landscape.
For investors, monitoring progress in the NMPA approval process and any announcements from management regarding further partnerships or clinical results will be critical. As CBSC continues to roll out its expansion strategy, it is advisable to reassess positions based on the company's execution and market reception in China. Investors should remain cautious but optimistic as developments unfold in the coming months, ensuring they stay updated with timely announcements from the management team.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAS VEGAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) (“CBSC” or the “Company”), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, today provided an update on the execution of its China market entry plan for its MyCardia AT cardiac event monitoring device.
The Company has formally initiated manufacturing and regulatory preparation activities in China through its contract manufacturing and regulatory partner Ebulent Medical (Shenzhen) Ltd., a licensed National Medical Products Administration (NMPA) medical device manufacturer.
CBSC has recently delivered printed circuit assemblies, components, and accessories for the MyCardia AT system to Ebulent in Shenzhen. A secure cloud-based data room containing the full manufacturing package, including bills of materials, assembly instructions, validation software, testing protocols, and packaging documentation, has been activated and is being used by Ebulent to build its NMPA-compliant manufacturing file and Device History File (DHF).
Ebulent has also begun configuring its production line and post-assembly validation stations for the MyCardia AT and is scheduled to complete an initial manufacturing run by month-end. As required to complete the NMPA approval process, these devices will be placed into active hospital accounts in China for in-hospital clinical field testing, building on the Company’s existing clinical trial which recently topped five million prior patient procedures.
Following this final successful device validation in hospital use, Ebulent will register as CBSC’s Chinese manufacturing partner with the NMPA, and since Ebulent is already an NMPA-approved medical device manufacturer, the registration formality is expected to be a filing-based process. CBSC, Ebulent, and CBSC’s Chinese clinical partners will then submit the final regulatory dossier to the NMPA advisory board for commercial clearance of the MyCardia AT device in China.
“This partnership gives us direct access to a fully licensed Chinese medical-device manufacturing and regulatory infrastructure,” said Charles Martin, Chief Executive Officer of CBSC. “We believe that Ebulent’s scale, quality systems, and regulatory standing significantly strengthen our ability to achieve NMPA clearance and commercialize MyCardia AT in China.”
This China initiative represents another significant milestone in the Company’s mission to provide state-of-the-art cardiac monitoring solutions worldwide and builds on its recent international expansion including regulatory approval in Canada, and exclusive distribution agreements in Central and South America.
The MyCardia AT integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat, and produces a recurring revenue stream for the Company through a revenue-sharing model which varies by market reflecting regional healthcare economics and reimbursement practices.
As additional new developments occur, Cardiac Biotech Solutions, Inc. will make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About Cardiac Biotech Solutions, Inc.
Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
About Ebulent Medical (Shenzhen) Ltd.
Ebulent Medical (Shenzhen) Ltd., through its Shenzhen and Huizhou facilities, provides comprehensive contract development, regulatory, and manufacturing services for medical device companies. Its integrated R&D, quality systems, regulatory registration support, and advanced production capabilities enable the design, validation, and commercial manufacture of regulated medical devices for the Chinese and global healthcare markets.
Company Contact Information:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: X, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
FAQ**
How does CB Scientific Inc CBSC plan to leverage its partnership with Ebulent Medical to enhance its manufacturing capabilities for the MyCardia AT in China?
What specific regulatory milestones does CB Scientific Inc CBSC need to achieve with the NMPA for the successful commercial launch of MyCardia AT in the Chinese market?
In what ways does CB Scientific Inc CBSC's North American experience influence its strategy for entering the Chinese market for cardiac monitoring solutions?
What potential challenges does CB Scientific Inc CBSC foresee in the clinical validation and subsequent NMPA clearance process for the MyCardia AT device in China?
**MWN-AI FAQ is based on asking OpenAI questions about CB Scientific Inc (OTC: CBSC).
NASDAQ: CBSC
CBSC Trading
0.0% G/L:
$0.04 Last:
13,000 Volume:
$0.04 Open:
